Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

about

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Item

http://www.wikidata.org/entity/Q57169747

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@en

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@nl

type

Item

label

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@en

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@nl

prefLabel

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@en

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@nl

P1476

Secukinumab in the treatment o ...... mised phase III FUTURE 1 trial

@en

P2093

Andreas Reimold

http://www.w3.org/2001/XMLSchema#string

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

Evie Maria Delicha

http://www.w3.org/2001/XMLSchema#string

Hasan Tahir

http://www.w3.org/2001/XMLSchema#string

Jürgen Rech

http://www.w3.org/2001/XMLSchema#string

Luminita Pricop

http://www.w3.org/2001/XMLSchema#string

Pascale Pellet

http://www.w3.org/2001/XMLSchema#string

Philip J Mease

http://www.w3.org/2001/XMLSchema#string

Piet Geusens

http://www.w3.org/2001/XMLSchema#string

Shephard Mpofu

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

Interleukin-17 and type 17 helper T cells

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion.

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

P304

e000723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2018-000723

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30167329

http://www.w3.org/2001/XMLSchema#string

P932

6109799

http://www.w3.org/2001/XMLSchema#string